EUROPE GAMBLES ON HIGH TECH

In increasing numbers, European financiers are shrugging off their traditional conservatism and discovering the definition of venture capital that their U.S. cousins have always embraced taking a chance on an unproven idea or technology. To be sure, the spirit of risk taking varies from country to country—the U.K. is much more daring than West Germany, for example. But according to accounting firm Peat Marwick McLintock, last year—for the first time ever—there was more venture

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

In increasing numbers, European financiers are shrugging off their traditional conservatism and discovering the definition of venture capital that their U.S. cousins have always embraced taking a chance on an unproven idea or technology. To be sure, the spirit of risk taking varies from country to country—the U.K. is much more daring than West Germany, for example. But according to accounting firm Peat Marwick McLintock, last year—for the first time ever—there was more venture capital available in Europe then in the US. ($4.3 billion vs. $4.2 billion). And these funds are footing the bill for more and more European high-tech startups.

Entrepreneurism has long been stifeld in Europe by high taxes and a staunch aversion to risky business. “Ten years ago we did a study of young technology-based firms in the U.K. and Germany, and could find hardly any examples, recalls Kamel Saad, vice president of Arthur D. Little Inc. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies